{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:00:52Z","timestamp":1777658452378,"version":"3.51.4"},"reference-count":119,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>The pituitary gland is considered the conductor of the hormonal orchestra, and despite its small dimensions, numerous tumoral lesions can arise within it. Over the past decade, substantial changes have been made regarding the nomenclature, which are summarized in the 5th Edition of the World Health Organization Classification of Endocrine and Neuroendocrine Tumors. Furthermore, significant breakthroughs in biomolecular mechanisms have been uncovered, which have formed the basis for the new classification. The management of these lesions varies according to several factors such as tumoral dimensions, hormonal activity, symptomatology, and radiological findings. At the same time, the therapeutic goal is represented by normalization of hormonal hypersecretion if present, control of tumoral growth and\/or relief of mass effect symptoms, and preservation or restoration of the pituitary function. The current narrative review aims to explore the link between biomolecular aspects, the extent of resectability, and the postoperative outcome.<\/jats:p>","DOI":"10.3390\/medicina61111973","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:18:42Z","timestamp":1762186722000},"page":"1973","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The PitNET Puzzle: From Zero to Linking Molecular Behavior with Neurosurgical Aspects"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0739-3224","authenticated-orcid":false,"given":"Amira","family":"Kamel","sequence":"first","affiliation":[{"name":"Neurosurgical Department, Bagdasar-Arseni Clinical Emergency Hospital, 041915 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6788-5833","authenticated-orcid":false,"given":"Ligia Gabriela","family":"Tataranu","sequence":"additional","affiliation":[{"name":"Neurosurgical Department, Bagdasar-Arseni Clinical Emergency Hospital, 041915 Bucharest, Romania"},{"name":"Neurosurgical Department, Carol Davila University of Medicine and Pharmacy, 020022 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca-Cristina","family":"Cristutiu","sequence":"additional","affiliation":[{"name":"Neurosurgical Department, Bagdasar-Arseni Clinical Emergency Hospital, 041915 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3039-857X","authenticated-orcid":false,"given":"Anica","family":"Dricu","sequence":"additional","affiliation":[{"name":"Biochemistry Department, Carol Davila University of Medicine and Pharmacy, 020022 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3848-0893","authenticated-orcid":false,"given":"Radu Eugen","family":"Rizea","sequence":"additional","affiliation":[{"name":"Neurosurgical Department, Bagdasar-Arseni Clinical Emergency Hospital, 041915 Bucharest, Romania"},{"name":"Neurosurgical Department, Carol Davila University of Medicine and Pharmacy, 020022 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-Tumor Endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/cncr.20412","article-title":"The prevalence of pituitary adenomas: A systematic review","volume":"101","author":"Ezzat","year":"2004","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1210\/jc.2006-1668","article-title":"High prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium","volume":"91","author":"Daly","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1530\/EJE-14-0144","article-title":"The incidence rate of pituitary adenomas in western Sweden for the period 2001\u20132011","volume":"171","author":"Gunnarsson","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s11604-023-01400-7","article-title":"Imaging of pituitary tumors: An update with the 5th WHO Classifications-part 1. Pituitary neuroendocrine tumor (PitNET)\/pituitary adenoma","volume":"41","author":"Tsukamoto","year":"2023","journal-title":"Jpn. J. Radiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.21037\/tcr-20-3446","article-title":"Pituitary adenoma or pituitary neuroendocrine tumor: A narrative review of controversy and perspective","volume":"10","author":"Liu","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO Classification of Pituitary Tumors","volume":"33","author":"Asa","year":"2022","journal-title":"Endocr. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s11102-019-00988-2","article-title":"A tale of pituitary adenomas: To NET or not to NET: Pituitary Society position statement","volume":"22","author":"Ho","year":"2019","journal-title":"Pituitary"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s11102-019-01027-w","article-title":"The tale in evolution: Clarity, consistency and consultation, not contradiction and confusion","volume":"23","author":"Ho","year":"2020","journal-title":"Pituitary"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.14791\/btrt.2023.0015","article-title":"Pituitary Neuroendocrine Tumor: Is It Benign or Malignant?","volume":"11","author":"Lee","year":"2023","journal-title":"Brain Tumor Res. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00428-019-02655-0","article-title":"A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): A European Pituitary Pathology Group (EPPG) proposal","volume":"475","author":"Villa","year":"2019","journal-title":"Virchows Arch."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12022-021-09663-4","article-title":"Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?","volume":"32","author":"Asa","year":"2021","journal-title":"Endocr. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and Treatment of Pituitary Adenomas: A Review","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11060-014-1386-5","article-title":"The pituitary stalk effect: Is it a passing phenomenon?","volume":"117","author":"Bergsneider","year":"2014","journal-title":"J. Neurooncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11060-013-1354-5","article-title":"Epidemiology and etiopathogenesis of pituitary adenomas","volume":"117","author":"Aflorei","year":"2014","journal-title":"J. Neurooncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s11604-021-01121-9","article-title":"The utility of dynamic MRI in differentiating the hormone-producing ability of pituitary adenomas","volume":"39","author":"Amano","year":"2021","journal-title":"Jpn. J. Radiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ejrad.2014.03.011","article-title":"Diffusion-weighted imaging of the sellar region: A comparison study of BLADE and single-shot echo planar imaging sequences","volume":"83","author":"Yiping","year":"2014","journal-title":"Eur. J. Radiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3174\/ajnr.A3564","article-title":"Arterial spin-labeled perfusion imaging reflects vascular density in nonfunctioning pituitary macroadenomas","volume":"34","author":"Sakai","year":"2013","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2463\/mrms.2014-0026","article-title":"Evaluation of the antiangiogenic effects of octreotide on growth hormone-producing pituitary adenoma using arterial spin-labeling perfusion imaging","volume":"14","author":"Sakai","year":"2015","journal-title":"Magn. Reson. Med. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s11102-016-0706-5","article-title":"Magnetic resonance elastography detects tumoral consistency in pituitary macroadenomas","volume":"19","author":"Hughes","year":"2016","journal-title":"Pituitary"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3171\/2021.6.JNS204425","article-title":"Predicting pituitary adenoma consistency with preoperative magnetic resonance elastography","volume":"136","author":"Helal","year":"2022","journal-title":"J. Neurosurg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.mayocp.2022.03.017","article-title":"Pituitary Adenoma Incidence, Management Trends, and Long-term Outcomes: A 30-Year Population-Based Analysis","volume":"97","author":"Graffeo","year":"2022","journal-title":"Mayo Clin. Proc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1210\/jc.2010-1048","article-title":"Pituitary incidentaloma: An endocrine society clinical practice guideline","volume":"96","author":"Freda","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1507\/endocrj.K08E-082","article-title":"Epigenetic control in pituitary tumors","volume":"55","author":"Ezzat","year":"2008","journal-title":"Endocr. J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Pease, M., Ling, C., Mack, W.J., Wang, K., and Zada, G. (2013). The role of epigenetic modification in tumorigenesis and progression of pituitary adenomas: A systematic review of the literature. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0082619"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.12659\/MSM.910608","article-title":"Overexpression of DNA (Cytosine-5)-Methyltransferase 1 (DNMT1) And DNA (Cytosine-5)-Methyltransferase 3A (DNMT3A) Is Associated with Aggressive Behavior and Hypermethylation of Tumor Suppressor Genes in Human Pituitary Adenomas","volume":"24","author":"Ma","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/neuonc\/noac050","article-title":"Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors","volume":"24","author":"Herrgott","year":"2022","journal-title":"Neuro-Oncology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1677\/ERC-09-0008","article-title":"Loss of neuronatin expression is associated with promoter hypermethylation in pituitary adenoma","volume":"16","author":"Revill","year":"2009","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF02789395","article-title":"cDNA cloning and mRNA expression analysis of the human neuronatin","volume":"9","author":"Usui","year":"1997","journal-title":"J. Mol. Neurosci."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lachkhem, A., Yahi, A., Kablia, S.O., Derriche, A., Staifi, A., and Derradji, H. (2023, January 13\u201316). Null cell adenoma: Case report. Proceedings of the 25th European Congress of Endocrinology, Istanbul, Turkey.","DOI":"10.1530\/endoabs.90.EP867"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1186\/s12967-024-05702-w","article-title":"Comprehensive transcriptomic analysis identifies three distinct subtypes of pituitary adenomas: Insights into tumor behavior, prognosis, and stem cell characteristics","volume":"22","author":"Peng","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_32","first-page":"69","article-title":"Plurihormonal pituitary adenomas","volume":"3","author":"Scheithauer","year":"1986","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_34","unstructured":"Yatavelli, R.K.R., and Bhusal, K. (2025). Prolactinoma. StatPearls, StatPearls Publishing LLC."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000495184","article-title":"Giant Prolactinomas","volume":"109","author":"Shimon","year":"2019","journal-title":"Neuroendocrinology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000499382","article-title":"Clinical, Pathological, and Molecular Factors of Aggressiveness in Lactotroph Tumours","volume":"109","author":"Trouillas","year":"2019","journal-title":"Neuroendocrinology"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Tataranu, L.G. (2025). A Brief Overview of Molecular Biology in Pituitary Adenomas with a Focus on Aggressive Lesions. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26083717"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s40618-017-0725-8","article-title":"Frequency of familial pituitary adenoma syndromes among patients with functioning pituitary adenomas in a reference outpatient clinic","volume":"40","author":"Marques","year":"2017","journal-title":"J. Endocrinol. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1365-2265.2008.03266.x","article-title":"Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas","volume":"69","author":"Georgitsi","year":"2008","journal-title":"Clin. Endocrinol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1530\/EJE-11-0304","article-title":"High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas","volume":"165","author":"Tichomirowa","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/17446651.2017.1306439","article-title":"Sporadic pituitary adenomas: The role of germline mutations and recommendations for genetic screening","volume":"12","author":"Iacovazzo","year":"2017","journal-title":"Expert. Rev. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6061\/clinics\/2012(Sup01)09","article-title":"Pituitary tumors in patients with MEN1 syndrome","volume":"67","author":"Syro","year":"2012","journal-title":"Clinics"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-12-0763","article-title":"Genetic analysis in young patients with sporadic pituitary macroadenomas: Besides AIP don\u2019t forget MEN1 genetic analysis","volume":"168","author":"Cuny","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/EJE-13-0503","article-title":"Giant prolactinomas in women","volume":"170","author":"Delgrange","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11102-016-0723-4","article-title":"Giant prolactinomas larger than 60 mm in size: A cohort of massive and aggressive prolactin-secreting pituitary adenomas","volume":"19","author":"Shimon","year":"2016","journal-title":"Pituitary"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000182496","article-title":"Prolactinomas and resistance to dopamine agonists","volume":"38","author":"Brue","year":"1992","journal-title":"Horm. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-12-0236","article-title":"Prolactinomas resistant to standard doses of cabergoline: A multicenter study of 92 patients","volume":"167","author":"Vroonen","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00701-005-0498-2","article-title":"Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance","volume":"147","author":"Delgrange","year":"2005","journal-title":"Acta Neurochir."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1210\/mend.13.1.0225","article-title":"Structure, Expression, and Function of Human Pituitary Tumor-Transforming Gene (PTTG)","volume":"13","author":"Zhang","year":"1999","journal-title":"Mol. Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1210\/jcem.84.2.5432","article-title":"Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas","volume":"84","author":"Zhang","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1038\/onc.2013.278","article-title":"Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas","volume":"33","author":"Rugowski","year":"2014","journal-title":"Oncogene"},{"key":"ref_52","first-page":"818","article-title":"Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker","volume":"82","author":"Bates","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1750-3639.2011.00476.x","article-title":"Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors","volume":"21","author":"Wierinckx","year":"2011","journal-title":"Brain Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1097\/01.MP.0000039572.75188.1A","article-title":"Role of E-cadherin, alpha-, beta-, and gamma-catenins, and p120 (cell adhesion molecules) in prolactinoma behavior","volume":"15","author":"Qian","year":"2002","journal-title":"Mod. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1007\/BF01411124","article-title":"Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis","volume":"138","author":"Kawamoto","year":"1996","journal-title":"Acta Neurochir."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1210\/jcem.85.8.6754","article-title":"Role of matrix metalloproteinase 9 in pituitary tumor behavior","volume":"85","author":"Turner","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00401-003-0747-5","article-title":"Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue","volume":"106","author":"Knappe","year":"2003","journal-title":"Acta Neuropathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1210\/jc.2009-1191","article-title":"Prognostic factors in prolactin pituitary tumors: Clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up","volume":"95","author":"Raverot","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/CM9.0000000000000184","article-title":"Functioning gonadotroph adenoma","volume":"132","author":"Zhao","year":"2019","journal-title":"Chin. Med. J."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Ntali, G., and Capatina, C. (2022). Updating the Landscape for Functioning Gonadotroph Tumors. Medicina, 58.","DOI":"10.3390\/medicina58081071"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12022-017-9498-z","article-title":"Overview of the 2017 WHO Classification of Pituitary Tumors","volume":"28","author":"Mete","year":"2017","journal-title":"Endocr. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"E796","DOI":"10.1210\/jc.2012-4028","article-title":"Whole-Exome Sequencing Studies of Nonfunctioning Pituitary Adenomas","volume":"98","author":"Newey","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-17-0702","article-title":"Gene expression profiling of fast- and slow-growing non-functioning gonadotroph pituitary adenomas","volume":"178","author":"Falch","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.nec.2019.05.001","article-title":"Molecular Biology of Pituitary Adenomas","volume":"30","author":"Faltermeier","year":"2019","journal-title":"Neurosurg. Clin. N. Am."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Hussein, Z., Grieve, J., Dorward, N., Miszkiel, K., Kosmin, M., Fersht, N., Bouloux, P.M., Jaunmuktane, Z., Baldeweg, S.E., and Marcus, H.J. (2023). Non-functioning pituitary macroadenoma following surgery: Long-term outcomes and development of an optimal follow-up strategy. Front. Surg., 10.","DOI":"10.3389\/fsurg.2023.1129387"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1530\/EJE-07-0099","article-title":"Relevance of Ki-67 and prognostic factors for recurrence\/progression of gonadotropic adenomas after first surgery","volume":"157","author":"Dubois","year":"2007","journal-title":"Eur. J. Endocrinol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1227\/NEU.0000000000001188","article-title":"Functional Gonadotroph Adenomas: Case Series and Report of Literature","volume":"79","author":"Cote","year":"2016","journal-title":"Neurosurgery"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1016\/j.wneu.2018.08.043","article-title":"Nonfunctioning Pituitary Adenoma Recurrence and Its Relationship with Sex, Size, and Hormonal Immunohistochemical Profile","volume":"120","author":"Batista","year":"2018","journal-title":"World Neurosurg."},{"key":"ref_69","first-page":"e28722","article-title":"A Comprehensive Review of Four Clinical Practice Guidelines of Acromegaly","volume":"14","author":"Ogedegbe","year":"2022","journal-title":"Cureus"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/s41379-018-0016-8","article-title":"Epidemiology and biomarker profile of pituitary adenohypophysial tumors","volume":"31","author":"Mete","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Asa, S.L., and Ezzat, S. (2021). An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism. J. Clin. Med., 10.","DOI":"10.3390\/jcm10112254"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.humpath.2020.10.004","article-title":"Cytokeratin profiles in pituitary neuroendocrine tumors","volume":"107","author":"Asa","year":"2021","journal-title":"Hum. Pathol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12020-014-0383-y","article-title":"Growth hormone tumor histological subtypes predict response to surgical and medical therapy","volume":"49","author":"Carlson","year":"2015","journal-title":"Endocrine"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/cen.14465","article-title":"Preoperative prediction of granulation pattern subtypes in GH-secreting pituitary adenomas","volume":"95","author":"Heng","year":"2021","journal-title":"Clin. Endocrinol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Yan, J.L., Chen, M.Y., Chen, Y.L., Chuang, C.C., Hsu, P.W., Wei, K.C., and Chang, C.N. (2022). Surgical Outcome and Evaluation of Strategies in the Management of Growth Hormone-Secreting Pituitary Adenomas After Initial Transsphenoidal Pituitary Adenectomy Failure. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.756855"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11102-020-01096-2","article-title":"Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: A single center experience from a cohort of 131 patients with acromegaly","volume":"24","author":"Swanson","year":"2021","journal-title":"Pituitary"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/EJE-10-0586","article-title":"Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae","volume":"163","author":"Bakhtiar","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3171\/2013.8.JNS13224","article-title":"Treatment of acromegaly by endoscopic transsphenoidal surgery: Surgical experience in 214 cases and cure rates according to current consensus criteria","volume":"119","author":"Hazer","year":"2013","journal-title":"J. Neurosurg."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.lpm.2008.10.008","article-title":"Corticotroph adenoma","volume":"38","author":"Guignat","year":"2009","journal-title":"Presse Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1227\/01.neu.0000429858.96652.1e","article-title":"A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas","volume":"73","author":"Jahangiri","year":"2013","journal-title":"Neurosurgery"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40618-018-0901-5","article-title":"Advances and controversies in the classification and grading of pituitary tumors","volume":"42","author":"Laws","year":"2019","journal-title":"J. Endocrinol. Investig."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s40478-025-02050-8","article-title":"Transcription factor-based classification of pituitary adenomas\/PitNETs: A comparative analysis and clinical implications across WHO 2004, 2017 and 2022 in 921 cases","volume":"13","author":"Hladik","year":"2025","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1530\/EJE-15-0689","article-title":"The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing\u2019s disease","volume":"174","author":"Hayashi","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12020-018-1776-0","article-title":"Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomas","volume":"63","author":"Losa","year":"2019","journal-title":"Endocrine"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Nerubenko, E., Ryazanov, P., Kuritsyna, N., Paltsev, A., Ivanova, O., Grineva, E., Kostareva, A., Dmitrieva, R., and Tsoy, U. (2024). Cushing\u2019s Disease Manifestation in USP8-Mutated Corticotropinoma May Be Mediated by Interactions Between WNT Signaling and SST Trafficking. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252312886"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/neuonc\/noz109","article-title":"Driver mutations in USP8 wild-type Cushing\u2019s disease","volume":"21","author":"Sbiera","year":"2019","journal-title":"Neuro-Oncology"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Kober, P., Rusetska, N., Mossakowska, B.J., Maksymowicz, M., P\u0119kul, M., Zieli\u0144ski, G., Styk, A., Kunicki, J., Dzia\u0142ach, \u0141., and Witek, P. (2023). The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing\u2019s disease and silent corticotroph tumors. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1124646"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s40478-022-01437-1","article-title":"TP53 mutations in functional corticotroph tumors are linked to invasion and worse clinical outcome","volume":"10","author":"Simon","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/clinem\/dgaa853","article-title":"USP8 and TP53 Drivers are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors","volume":"106","author":"Uzilov","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"P\u0119kul, M., Szczepaniak, M., Kober, P., Rusetska, N., Mossakowska, B.J., Baluszek, S., Kowalik, A., Maksymowicz, M., Zieli\u0144ski, G., and Kunicki, J. (2024). Relevance of mutations in protein deubiquitinases genes and TP53 in corticotroph pituitary tumors. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1302667"},{"key":"ref_91","first-page":"e1183","article-title":"Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations","volume":"106","author":"Boldt","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e13169","DOI":"10.1111\/jne.13169","article-title":"Aggressive corticotroph tumors and carcinomas","volume":"34","author":"Lasolle","year":"2022","journal-title":"J. Neuroendocrinol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Dai, C., Feng, M., Lu, L., Sun, B., Fan, Y., Bao, X., Yao, Y., Deng, K., Wang, R., and Kang, J. (2022). Transsphenoidal Surgery of Corticotroph Adenomas With Cavernous Sinus Invasion: Results in a Series of 86 Consecutive Patients. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.810234"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1023\/A:1012917701756","article-title":"Thyrotropin-secreting pituitary adenomas. Clinical and biological heterogeneity and current treatment","volume":"54","author":"Sanno","year":"2001","journal-title":"J. Neurooncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000351007","article-title":"2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors","volume":"2","author":"Lania","year":"2013","journal-title":"Eur. Thyroid. J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/1043-2760(92)90001-H","article-title":"G protein oncogenes in pituitary tumors","volume":"3","author":"Spada","year":"1992","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF02914458","article-title":"Immunohistochemical study of p53 protein in human and animal pituitary tumors","volume":"4","author":"Sumi","year":"1993","journal-title":"Endocr. Pathol."},{"key":"ref_98","first-page":"1134","article-title":"Screening of candidate oncogenes in human thyrotroph tumors: Absence of activating mutations of the G alpha q, G alpha 11, G alpha s, or thyrotropin-releasing hormone receptor genes","volume":"81","author":"Dong","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/BF03343929","article-title":"Loss of heterozygosity of the MEN1 gene in a large series of TSH-secreting pituitary adenomas","volume":"24","author":"Asteria","year":"2001","journal-title":"J. Endocrinol. Investig."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00401-004-0863-x","article-title":"Pathological study of thyrotropin-secreting pituitary adenoma: Plurihormonality and medical treatment","volume":"108","author":"Teramoto","year":"2004","journal-title":"Acta Neuropathol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11102-005-3759-4","article-title":"Clinical and Molecular Features of a TSH-Secreting Pituitary Microadenoma","volume":"8","author":"Usui","year":"2005","journal-title":"Pituitary"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ando.2019.06.006","article-title":"Diagnosis, pathology, and management of TSH-secreting pituitary tumors. A single-center retrospective study of 20 patients from 1981 to 2014","volume":"80","author":"Gaillard","year":"2019","journal-title":"Ann. Endocrinol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3171\/2014.7.JNS1471","article-title":"Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: A single-center study of 90 cases","volume":"121","author":"Yamada","year":"2014","journal-title":"J. Neurosurg."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Luo, P., Zhang, L., Yang, L., An, Z., and Tan, H. (2020). Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.580264"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s12022-017-9503-6","article-title":"Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas","volume":"28","author":"Lee","year":"2017","journal-title":"Endocr. Pathol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Woo, C.S., Ho, R.S., Ho, G., Lau, H.T., Fong, C.H., Chang, J.Y., Leung, E.K., Tang, L.C., Ma, I.K., and Lee, A.C. (2024). A clinicopathological study of non-functioning pituitary neuroendocrine tumours using the World Health Organization 2022 classification. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1368944"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12022-014-9347-2","article-title":"Null cell adenomas of the pituitary gland: An institutional review of their clinical imaging and behavioral characteristics","volume":"26","author":"Balogun","year":"2015","journal-title":"Endocr. Pathol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s007010050285","article-title":"Expression of P27kip1 and Ki-67 in pituitary adenomas: An investigation of marker of adenoma invasiveness","volume":"141","author":"Zhao","year":"1999","journal-title":"Acta Neurochir."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00701-004-0298-0","article-title":"Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha","volume":"146","author":"Wolfsberger","year":"2004","journal-title":"Acta Neurochir."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e765","DOI":"10.1016\/j.wneu.2019.06.217","article-title":"Clinicopathologic Characteristics and Surgical Treatment of Plurihormonal Pituitary Adenomas","volume":"130","author":"Aydin","year":"2019","journal-title":"World Neurosurg."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3171\/2020.2.JNS2018","article-title":"Expression of additional transcription factors is of prognostic value for aggressive behavior of pituitary adenomas","volume":"134","author":"Micko","year":"2021","journal-title":"J. Neurosurg."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2265.2008.03514.x","article-title":"Silent subtype 3 pituitary adenoma: A clinicopathologic analysis of the Mayo Clinic experience","volume":"71","author":"Erickson","year":"2009","journal-title":"Clin. Endocrinol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/modpathol.2015.151","article-title":"Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas","volume":"29","author":"Mete","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12022-023-09755-3","article-title":"Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future","volume":"34","year":"2023","journal-title":"Endocr. Pathol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Voellger, B., Zhang, Z., Benzel, J., Wang, J., Lei, T., Nimsky, C., and Bartsch, J.W. (2021). Targeting Aggressive Pituitary Adenomas at the Molecular Level-A Review. J. Clin. Med., 11.","DOI":"10.3390\/jcm11010124"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41016-017-0109-0","article-title":"Role of matrix Metalloproteinases in pituitary adenoma invasion","volume":"4","author":"Yang","year":"2018","journal-title":"Chin. Neurosurg. J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3803\/EnM.2020.875","article-title":"Associations of GNAS Mutations with Surgical Outcomes in Patients with Growth Hormone-Secreting Pituitary Adenoma","volume":"36","author":"Jung","year":"2021","journal-title":"Endocrinol. Metab."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Chang, M., Yang, C., Bao, X., and Wang, R. (2021). Genetic and Epigenetic Causes of Pituitary Adenomas. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.596554"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1210\/er.2012-1013","article-title":"Familial Isolated Pituitary Adenomas (FIPA) and the Pituitary Adenoma Predisposition due to Mutations in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene","volume":"34","author":"Beckers","year":"2013","journal-title":"Endocr. Rev."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1973\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:37:05Z","timestamp":1762321025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":119,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["medicina61111973"],"URL":"https:\/\/doi.org\/10.3390\/medicina61111973","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]}}}